ACTOS

LOE Approaching

pioglitazone

NDAORALTABLETPriority Review
Approved
Jul 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

action. ACTOS decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma…

Clinical Trials (5)

NCT07444424Phase 1Not Yet Recruiting

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants

Started Mar 2026
32 enrolled
Healthy Participants
NCT06989723Phase 4Recruiting

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

Started Jan 2025
NCT06594172Phase 2Not Yet Recruiting

Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy

Started Sep 2024
NCT06571591Phase 3Active Not Recruiting

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

Started Aug 2024
582 enrolled
T2DM
NCT06164665Phase 4Completed

Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude

Started Mar 2023
9 enrolled
High Altitude